Immuno-Oncology: From Science Fiction to the Mainstream
In just a couple of decades, immuno-oncology has taken center stage in the biotechnology industry.…
In just a couple of decades, immuno-oncology has taken center stage in the biotechnology industry.…
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled…
European biotech companies are flocking to the Nasdaq Stock Market in 2020, but not all…
The German biotech Immatics will partner with GSK and could receive more than €1B from…
The field of immuno-oncology has expanded out of all recognition over the last few years.…
The US company Celgene has obtained options to three cancer immunotherapy programs from the German…
A European trial has proved the feasibility and efficacy of treating cancer with a personalized…
Besides struggling with ambitious New Year’s resolutions and post-holiday diets, January is a time where…
Immatics has completed a $58M (€50M) round with the participation of Amgen, not long after both…
A Phase I study will investigate the safety and tolerability of Immatics approach to treating…
Immatics will start a first clinical trial to test IMA101, a personalized cell therapy with…
While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for…